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PERSPECTIVE
Control of fecal–orally transmitted pathogens is inad-
equate in many developing countries, in particular, in sub-
Saharan Africa. Acquired resistance to antimicrobial drugs 
is becoming more prevalent among Vibrio cholerae, Salmo-
nella enteritidis, diarrheagenic Escherichia coli, and other 
pathogens in this region. The poor, who experience most 
of the infections caused by these organisms, bear the brunt 
of extended illness and exacerbated proportion of deaths 
brought about by resistance. Improved antimicrobial drug 
stewardship is an often cited, but inadequately implemented, 
intervention for resistance control. Resistance containment 
also requires improvements in infectious disease control, 
access to and quality assurance of antimicrobial agents, as 
well as diagnostic facilities. Structural improvements along 
these lines will also enhance disease prevention and control 
as well as rational antimicrobial drug use. Additionally, more 
research is needed to identify low-cost, high-impact inter-
ventions for resistance control.
T
he adverse effects of infectious diseases in many de-
veloping countries is considerable and, within those 
countries, economically disadvantaged persons are most 
likely to contract communicable diseases and least likely 
to access appropriate treatment (1,2). Many bacterial and 
parasitic diseases could, until recently, be treated with in-
expensive antimicrobial agents, but treatment has recently 
been made more expensive and less successful by the emer-
gence and spread of resistant organisms. Drug resistance is 
a large and growing problem in infections that account for 
most of Africa’s disease burden, including malaria, tuber-
culosis (TB), HIV infection, and respiratory and diarrheal 
diseases. The proportion of malaria infections resulting in 
death has increased in Africa, largely due to resistance, and 
the cost of effective antimalarial agents is higher than the 
health budgets of malaria-endemic countries can accommo-
date (3). Similarly, a recent outbreak of extensively drug-
resistant TB in rural South Africa illustrated that resistant 
organisms pose an enormous and costly threat to HIV-in-
fected persons and their HIV-negative contacts (4).
Much of the current discourse on infectious disease 
and drug resistance as it affects sub-Saharan Africa is lim-
ited to the pressing problems associated with HIV, TB, 
and malaria. Resistance, however, equally compromises 
the management of acute respiratory infections, sexually 
transmitted diseases, and diseases spread by the fecal–oral 
route, such as typhoid fever, cholera, dysentery, and other 
diarrheal diseases, which are the focus of this perspective. 
Moreover, young children are especially likely to acquire 
resistant enteric infections, from which they can experience 
less obvious, but long-term adverse effects.
Increased Antimicrobial Drug 
Resistance in Enteric Bacteria
Cholera toxin–producing Vibrio cholerae cause the 
characteristic life-threatening gastroenteritis, cholera. At 
least 7 pandemics of the disease, originally designated 
“Asiatic cholera,” have occurred in recent history. The 
ongoing pandemic has seen the emergence of O139 V. 
cholerae, as a non-O1 pandemic strain and, importantly, 
the emergence and spread of drug-resistant O1 strains. The 
current focus of the cholera pandemic is Africa, which has 
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seen two thirds of all cholera outbreaks in the last decade 
(5). The primary treatment for cholera is rehydration. Most 
patients will overcome the infection if they are rehydrated 
promptly and properly, even if they do not receive antimi-
crobial drugs. Antimicrobial drugs, however, shorten the 
course of infection and prevent person-to-person transmis-
sion, which may be crucial for slowing outbreaks because 
organisms from infected persons may be more virulent than 
those acquired in the wild (6). Antimicrobial agents may 
also be life-saving for malnourished and other immuno-
compromised patients who have cholera.
Tetracycline was the empiric drug of choice for chol-
era in Africa and elsewhere for many years. At the end of 
the 1970s, however, incompatibility group C tetracycline-
resistant plasmids were isolated from V. cholerae isolates 
in Tanzania, Kenya, and other parts of Africa (7,8). In 
each case, resistance emerged during an ongoing epidemic 
where tetracycline was being used intensively for prophy-
laxis as well as treatment. Tetracycline has sequentially 
been replaced by trimethoprim-sulfamethoxazole and, 
more recently, quinolones, because of the emergence and 
spread of resistant strains. Molecular evaluation of more 
recent resistant V. cholerae isolates typically found re-
gionally conserved plasmids, some of which carried class 
1 integrons bearing multiple resistance cassettes (9,10). A 
chromosomally integrated transferable resistance element, 
SXT, has also spread worldwide and has been recently re-
ported from Africa (9).
Emergence of resistance in V. cholerae has been 
linked to increased mortality rates in recent African out-
breaks. Similar experiences have also been reported with 
Shigella dysenteriae type 1, another enteric pathogen that 
causes life-threatening disease and has epidemic potential. 
The impact of resistance in both pathogens is illustrated by 
an overwhelming outbreak in July 1994 at the Goma camp, 
which resulted in the deaths of ≈12,000 Rwandan refu-
gees (11). More recently, Dalsgaard et al. (12) observed a 
marked increase in case-fatality rate during the 1997–1998 
phase of a Guinea-Bissau cholera outbreak, compared to an 
overlapping 1996–1997 outbreak. A major feature of the 
latter wave of cholera was the presence of strains simulta-
neously resistant to ampicillin, erythromycin, tetracycline, 
furazolidone, aminoglycosides, trimethoprim, and sulfa-
methoxazole. These multidrug-resistant strains were not 
present during the ﬁ  rst wave and probably arose following 
the acquisition of a 150-kb–pair resistance plasmid bearing 
a class 1 integron and genes encoding resistance to all an-
timicrobial agents commonly used in empiric management 
of cholera.
The emergence and spread of multidrug-resistant Sal-
monella enterica subsp. Typhi worldwide has had impor-
tant consequences for mortality rates from typhoid fever 
(13). There are very few reports from Africa; nonetheless, 
available data suggest that although the problem may not 
be as intense as in other parts of the world, resistance has 
emerged, and alternatives to current treatment protocols 
are often not available or unaffordable. Multidrug-resistant 
nontyphoidal Salmonella spp. (NTS) have emerged as a 
global public health threat. In industrialized countries, they 
are most commonly associated with foodborne gastroen-
teritis. In parts of sub-Saharan Africa, however, NTS are 
important causes of life-threatening bacteremia. Studies 
from Kenya have found that community-acquired NTS are 
among the top 3 causes of death among children <5 years 
of age (14,15). Moreover, pulsed-ﬁ  eld gel electrophoresis 
data suggest that most life-threatening disease is caused 
by isolates that are clonal in origin (14). In a recent study, 
children from poor slums of Kenya were signiﬁ  cantly more 
likely to be infected with multidrug-resistant NTS than 
were children from middle-income families (14). The pat-
terns of resistance among these strains suggest that third-
generation cephalosporins should be the drug of choice for 
empiric management of these infections, but in most cases, 
these drugs are too expensive.
Antimicrobial drug resistance is a large and growing 
problem among organisms that cause diarrheal disease. 
Although most diarrheal diseases are self-resolving and 
should not be treated with antimicrobial agents, inva-
sive or protracted infections require chemotherapy and 
are typically managed empirically. Recent data from 
Gabon, Nigeria, and Tanzania suggest that resistance 
among causative organisms of these infections, such as 
enterotoxigenic, enteropathogenic, and enteroaggregative 
Escherichia coli, is high and appears to be rising (16–18). 
Although oral rehydration therapy has drastically reduced 
deaths from the disease, prolonged infectious bouts of 
diarrhea have long-term consequences for physical and 
cognitive development. Very few reports have examined 
the epidemiology of diarrheal pathogens and even fewer 
have looked at drug resistance. Notable drug-resistant en-
teropathogenic E. coli outbreaks and sporadic cases have 
been reported from several African countries, including 
Kenya and Tanzania (16,19). The more recently deﬁ  ned 
enteroaggregative E. coli are typically multidrug-resistant 
and are one of the most common causes of childhood diar-
rhea, particularly persistent infections (20). Antimicrobial 
drug–resistant diarrheagenic E. coli pathotypes, including 
enteroaggregative E. coli, are also emerging as important 
diarrheal pathogens in AIDS patients (21).
Surveillance in healthy populations has demonstrated 
that commensals constitute a rich reservoir of genetic mate-
rial from which pathogens can readily acquire resistance on 
mobile elements. A long-term study in Nigeria showed that 
resistance of commensal E. coli to almost all agents studied 
increased rapidly over time (22). Additionally, urban resi-
dents in Nigeria, Ghana, and Zimbabwe were more likely 
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to carry multidrug-resistant E. coli than were rural or pro-
vincial residents (23,24). This ﬁ  nding has important con-
sequences in light of the rapid rate of urbanization in these 
countries and other parts of the continent. Travel networks 
have become more efﬁ  cient and are more extensively used. 
Therefore, just as Africa has had to deal with imported re-
sistant organisms, resistant strains that emerge or are am-
pliﬁ  ed in Africa will be exported (25,26).
Two overlapping problems are worsening the situation 
regarding diarrheal disease within Africa: the failure to con-
trol the spread of diarrheal pathogens, due to unclean water, 
poor sanitation, and malnutrition; and the failure to contain 
resistant organisms and resistant genes so that, when infec-
tions occur, they produce more adverse consequences. It is 
perhaps obvious, if unaddressed, that poor and displaced 
persons in Africa are least likely to be able to access po-
table water, safe sanitation, and other factors to prevent 
fecal–oral infection and that public health facilities need 
to be strengthened to protect the poor (27,28). However, 
the poor also disproportionately bear consequences from 
drug resistance, and interventions to curb the current trend 
are sorely needed. Economists describe a situation in which 
the decision to use a commodity that produces a deleteri-
ous byproduct that imposes costs on other persons, who are 
not part of the decision, as a negative externality. Because 
resistance is an externality, the poor are victims of the re-
sistance-predisposing activities of the afﬂ  uent, including 
the presence of visitors from other countries. Furthermore, 
resistance-promoting activities and the consequences of re-
sistance more often than not occur at a different time and 
place. It is therefore unrealistic to expect that the poor will 
mount resistance-curbing interventions as a priority with-
out prompting and support.
Overcoming Roadblocks to Containing 
Drug Resistance in Africa
There are difﬁ  culties associated with monitoring re-
sistance in many parts of Africa, but sufﬁ  cient published 
data exist to suggest that resistance rates are high and rising 
(22,29). In 2001, the World Health Organization issued a 
strategy for resistance containment (30). Most developing 
countries, particularly those in sub-Saharan Africa, have 
yet to implement any of the recommended interventions in 
spite of a mounting resistance crisis. Special risk factors for 
resistance, and roadblocks for evaluating and implement-
ing interventions, are linked to patient poverty and health 
system poverty. This is evident in sub-Saharan Africa, 
where we study resistance, but also in other developing 
countries.
Industrialized countries that are actively addressing 
community-acquired resistance have typically prioritized 
those interventions predicted to lower total antimicro-
bial agent consumption and therefore selective pressure 
(31,32). An important concern for poor countries is not 
the total amount of antimicrobial agents consumed, whose 
need exceeds the resources available, but the way these 
drugs are used. Diagnostic imprecision spurs overpre-
scribing, particularly of broad-spectrum agents, and low 
antimicrobial diversity promotes emergence and spread 
of potentially epidemic resistant clones. In Africa, medi-
cines are available from unorthodox sources and persons 
earning low daily wages often procure them 1 dose at a 
time. Sources include itinerant vendors, often encountered 
on buses in many African countries, who cannot always 
be located should a patient choose to purchase more doses 
later (Figure). Poor patients have little personal incentive 
to purchase more medicine than is needed to produce short-
term relief. Additionally, regimen fragmentation comes 
without sanction and allows for large price mark-ups and 
consequent exploitation. Therefore, distributors have every 
incentive to encourage antimicrobial drug misuse.
Quality Assurance
The relative scarcity of antimicrobial drugs in poor 
countries with a high prevalence of infectious diseases 
means that the demand for antimicrobial agents exceeds 
their supply. This imbalance, coupled with poor purchas-
ing power, makes sub-Saharan Africa and other developing 
regions a counterfeiters’ paradise. Substandard products 
with lower-than-stated doses promote resistance, and those 
containing no antimicrobial drug at all promote microbial 
dissemination. At least 30% of medicines sold in Africa 
are estimated to be counterfeit, with antimicrobial agents 
the most popular target (33). However, fake drugs are not 
the only poor quality pharmaceuticals on the market (34). 
Substandard drugs also include medicines that were appro-
priately manufactured but improperly stored. Proper stor-
age in the tropics requires expensive electrical equipment, 
a constant electricity supply, pharmaceutical handling 
expertise, and an efﬁ  cient supply chain, which do not ex-
ist in many parts of Africa. It has long been known that 
antibiotics are unstable at ambient tropical conditions, but 
shelf lives and packaging are not adapted to preserve drug 
potency or mark their degradation in countries where these 
drugs are most needed.
Antimicrobial Drug Supply and Distribution
Prescribing health workers and their patients, particu-
larly those who are poor, in sub-Saharan Africa continually 
battle a “drug is out of stock” syndrome. Rational antimi-
crobial drug policies, essential decision-support tools in the 
battle against resistance, are impossible to develop or to 
implement without an ensured supply of a reasonable range 
of drugs. Antimicrobial cycling has been piloted for anti-
malarial drugs in some parts of Africa, but more data are 
needed to gauge its effectiveness. Instituting and expanding 
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pilot programs have been hampered by drug supply issues, 
particularly the difﬁ  culty in removing cheaper, resistance-
compromised drugs, which are all the poor can afford, 
from the market (35). As long as demand for antimicrobial 
drugs exceeds their supply, uncontrolled and inadequate 
regimens will be the norm. To combat resistance in poor 
countries, antimicrobial agents will have to be made more 
available. For best results, when improved supply increas-
es selective pressure, drug misuse and resistant-strain dis-
semination must decline. Thus, antimicrobial drugs need to 
be made available along with the infrastructure to monitor 
their utility and improve selection. Special considerations 
are needed to encourage patients to procure and consume a 
complete regimen and to ensure antimicrobial drug quality 
as close to the point of care as possible. These are formi-
dable challenges because antimicrobial agents are available 
from unsanctioned, as well as sanctioned, providers and the 
former may have little or no training and unorthodox means 
of drug distribution.
Unrestricted access to antimicrobial drugs is perhaps 
the most favorable acknowledged predisposing situation 
for development of resistance. Ideas for promoting su-
pervised, or at least informed, access, however, need to 
advance beyond proposing improved legislation because 
most countries already have laws proscribing unsanctioned 
distribution. Illegal peddling is a function of inadequate 
law enforcement and the reality that drug selling provides a 
livelihood for otherwise underemployed persons. Notably, 
unofﬁ  cial outlets are the only source of life-saving medica-
tions for many rural residents in locations where enforc-
ing laws modeled on wealthy societies could do more harm 
than good. Until the infrastructure to effectively abolish 
unsanctioned drug distribution is available, incorporating 
informal distributors into a containment strategy may be 
the wisest option. Focusing interventions predominantly on 
formal health delivery systems enhances the quality of care 
available to the wealthy but neglects the supply chain on 
which the less privileged majority are largely dependent.
Enhanced Infectious Disease Control
The poverty–resistance cycle operates within a larger 
cycle of poverty and disease. Selective pressure for resis-
tance is, in almost all cases, a response to actual or supposed 
infection, and resistant bacteria are largely spread through 
the same routes as pathogens. One of the most effective 
means of conserving antimicrobial drugs is therefore pre-
venting infections. The effects of enteric infections in Af-
rica are almost entirely driven by poor access to safe water 
and sanitation. Thus, once resistant pathogens emerge, they 
are easily spread. The commensal reservoir of resistance 
genes spreads through the same channels, undetected but 
providing a ready source of resistance genes and elements 
that can be transmitted to pathogens. Middle-class and af-
ﬂ  uent Africans typically reside in the few areas where piped 
water is available or have private water supplies. Providing 
safe water and sanitation to those who cannot afford these 
capital-intensive options and to public institutions such as 
schools, health centers, and markets is the single most im-
portant intervention for preventing outbreaks and sporadic 
cases of diarrheal disease, including those caused by resis-
tant organisms.
Interventions that affect disease prevalence attack re-
sistance at the root of the problem and therefore have the 
greatest chance of success. Effective implementations of 
vaccination and drug use policies, such as the World Health 
Organization’s Integrated Management of Childhood Ill-
nesses, represent  examples that address community-ac-
quired infections that disproportionately affect economi-
cally disadvantaged populations (29). Unfortunately, even 
though the effectiveness of some of these interventions has 
been demonstrated, their access by poor populations is of-
ten not assured (36).
Malnourished or otherwise immunocompromised 
patients are more likely to have inadequate economic re-
sources, and they become the target of resistant pathogens 
when these organisms are prevalent (37). Patients infected 
with resistant strains pay more for cure, lose more from ex-
tended illness (in terms of time away from work and other 
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Figure. Itinerant medicine vendor in Oja-tuntun marketplace, Ile-Ife, 
Nigeria.PERSPECTIVE
activities, i.e., productivity, costs of supportive therapy), 
and are more likely to be disabled. In wealthy countries, 
hospitals are often the sites where resistance emerges, and 
then it slowly, but eventually, seeps into the community. In 
poor countries, often no barrier exists between the hospital 
and the community. A patient’s relatives, who must be on 
hand to assist overstretched health systems with care, sleep 
under beds and in hospital corridors. In hospitals, costly 
infection control measures are often compromised. The 
potential for organisms to be transmitted into, within, and 
beyond the hospital is very high.
Diagnostic Development
Diagnostic development represents a potentially pow-
erful strategy to simultaneously improve healthcare de-
livery and contain resistance (38,39). The cause of blood-
stream and enteric infections has diversiﬁ  ed considerably 
in recent years, in part due to the deﬁ  nition of previously 
unrecognized etiologic agents but also due to the spread of 
HIV and the emergence of new pathogens. This increased 
diversity makes syndromic diagnosis of many conditions 
less accurate, particularly in areas where surveillance does 
not occur. Better systems are needed to provide laboratory 
support for serious cases, outbreaks, and routine surveil-
lance. As disease control efforts begin to yield fruit, syn-
dromic diagnosis will become increasingly inaccurate and 
laboratory diagnosis even more essential.
If diagnostic tests for poor patients are subsidized as 
well as, or better than, medicines, health professionals and 
patients would be more likely to use them. Additionally, 
sentinel laboratory facilities will also provide data on local 
causes of infections and prevailing susceptibility patterns 
to inform local prescribing and alleviate the prevailing pov-
erty of information. Currently, studies that claim a global 
or worldwide coverage often exclude Africa so that as in 
the case of poor populations, the plight of poor countries, 
particularly as relevant to resistance, is underdocumented 
(40). Although programs outside Africa collate decades 
worth of susceptibility data, only 1 or 2 tertiary-level care 
centers in Nigeria and Ghana can produce complete records 
of susceptibility data from the past 5 years. Many African 
laboratories that perform susceptibility testing often can-
not collate, store, or disseminate surveillance data, even 
though open source software is available for the purpose 
(41). Much of the data they do generate is produced with 
antibiotic disks donated by pharmaceutical companies with 
a repertoire that does not necessarily reﬂ  ect the best choices 
for patients or even available stock. Diagnostic develop-
ment could also help alleviate the pressing need for antimi-
crobial drug quality assurance. Precise assessment of drug 
content is beyond the capabilities of a basic microbiology 
laboratory, but rudimentary diagnostic laboratories can be 
equipped to identify outright counterfeits and severely de-
graded antimicrobial agents. Finally, the weak laboratory 
capacity makes it difﬁ  cult to evaluate the success of inter-
ventions targeting resistance or other aspects of global dis-
ease control. Diagnostic microbiology laboratories should 
be considered an integral part of healthcare delivery in parts 
of the world where most patients visiting a health center 
have a microbial infection.
Conclusion
Resistance is encountered with virtually every infec-
tious disease. Few proven mechanisms exist for resistance 
control, and almost none have been validated in the devel-
oping-country setting. The dearth of intervention study data 
is particularly acute in the context where infectious disease 
prevalence is high and access to antimicrobial agents is 
low, which best describes the situation faced by low-in-
come persons in Africa. Most intervention studies in devel-
oping countries have focused on relatively inexpensive and 
easily piloted educational interventions. Educational inter-
ventions push against the strong inﬂ  uence of unregulated 
distribution, sometimes accompanied by unscrupulous 
counteradvertising, and their value has not been evaluated 
in the long run. Importantly, although educational interven-
tions typically yield positive results, these results are mod-
est (31). Other methods may in fact be more cost effective, 
or might boost the value of education. Strategies that have 
been evaluated and found to deal with the problem of resis-
tance need to be further diversiﬁ  ed in poor countries. Safe 
water and sanitation, addressing the imbalance between an-
timicrobial drug supply and demand, and building realistic 
infrastructure for rational antimicrobial use are priority ar-
eas for resistance control that could address the short- and 
long-term disease effects on the poor.
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